Provided by Tiger Trade Technology Pte. Ltd.

Trump Concept

3,236.42
+42.101.32%
Number of Gainers:18
Number of Losers:11
Number of Flat:2
PE:- -
High:3,260.68
Open:3,195.34
Low:3,195.34
Close:3,194.32
Volume:404.56M
Turnover:53.61B
Market Cap:6.14T
Float Cap:5.42T

Loading ...

Moderna, Concentrix, Boeing, HPE, Robinhood, Cal-Maine, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 30

Caterpillar to Invest $1 Billion in North Carolina to Expand Cat Compact Manufacturing Capacity

THOMSON REUTERS
·
Sep 30

Caterpillar - Project Expected to Create Advanced Manufacturing Careers and Skill Development Opportunities

THOMSON REUTERS
·
Sep 30

Caterpillar - Plans New Manufacturing Facility in Sanford, North Carolina

THOMSON REUTERS
·
Sep 30

Caterpillar - Facility to Incorporate Advanced Manufacturing Technologies and Automation

THOMSON REUTERS
·
Sep 30

What the History of Electric Wires Can Teach Us About the Data Center Backlash

InvestorPlace
·
Sep 30

Trump Media & Technology - Tae May Request Drawdowns up to $100 Mln During Second Tranche Draw Period - SEC Filing

THOMSON REUTERS
·
Sep 30

Trump Media & Technology - Tmtg and Tae Enter Amended Unsecured Convertible Promissory Note on Sept 30, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 30

Trump Media & Technology - Amended Note Issued with Initial Principal Amount of $200 Mln - SEC Filing

THOMSON REUTERS
·
Sep 30

U.S. Stocks on the MOVE-Boeing, Robinhood, Lumentum

Reuters
·
Sep 30

NOTIFICATION OF CHANGE OF THE STOCK BORROW RATE AND FUNDING SPREAD OF THE AFFECTED SECURITIES

GlobeNewswire
·
Sep 30

CTS Eventim AG & Co. KGaA (0EEE) Gets a Buy from J.P. Morgan

TIPRANKS
·
Sep 30

Tesla's Cash Crunch Has Arrived-Blame Its AI Ambitions

Dow Jones
·
Sep 30

Trump Media & Technology Group and Tae Technologies File Form S-4 Registration Statement for Proposed Merger

THOMSON REUTERS
·
Sep 30

Press Release: Trump Media & Technology Group and TAE Technologies File Form S-4 Registration Statement for Proposed Merger

Dow Jones
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30